New Delhi, March 17 -- Zydus Lifesciences on Tuesday announced a licensing and supply deal with Lupin Limited to broaden the availability of the diabetes medication Semaglutide Injection in 15 mg/3 ml dose via a user-friendly reusable pen in India.

As per the deal, Lupin is set to pay Zydus an initial licensing fee along with milestone-based payments upon reaching specific targets. This partnership focuses on enhancing patient reach for cutting-edge diabetes care and chronic weight management solutions.

"Under this agreement, Lupin will have semi-exclusive rights to co-market Zydus' innovative Semaglutide Injection in the Indian market under the brand names Semanext and Lupin's Livarise," Zydus said in a statement.

Dr Sharvil Patel, Ma...